ATE432997T1 - Therapieüberwachung für tumoren unter benutzung acc133 mrna - Google Patents

Therapieüberwachung für tumoren unter benutzung acc133 mrna

Info

Publication number
ATE432997T1
ATE432997T1 AT05710924T AT05710924T ATE432997T1 AT E432997 T1 ATE432997 T1 AT E432997T1 AT 05710924 T AT05710924 T AT 05710924T AT 05710924 T AT05710924 T AT 05710924T AT E432997 T1 ATE432997 T1 AT E432997T1
Authority
AT
Austria
Prior art keywords
disease
amount
treatment
individual
acc133
Prior art date
Application number
AT05710924T
Other languages
English (en)
Inventor
Maarten Penning
Den Broek Sebastiaan Van
Emile Voest
Laurens Beerepoot
Niven Mehra
Original Assignee
Primagen Holding Bv
Umc Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primagen Holding Bv, Umc Utrecht Holding Bv filed Critical Primagen Holding Bv
Application granted granted Critical
Publication of ATE432997T1 publication Critical patent/ATE432997T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05710924T 2004-03-02 2005-03-02 Therapieüberwachung für tumoren unter benutzung acc133 mrna ATE432997T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54945004P 2004-03-02 2004-03-02
EP04075686A EP1571225A1 (de) 2004-03-02 2004-03-02 Diagnose von Krankheiten und Überwachung einer Therapie unter Verwendung des AC133 Gens
PCT/NL2005/000155 WO2005083123A1 (en) 2004-03-02 2005-03-02 Diagnosis of (a risk of) disease and monitoring of therapy

Publications (1)

Publication Number Publication Date
ATE432997T1 true ATE432997T1 (de) 2009-06-15

Family

ID=34746048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05710924T ATE432997T1 (de) 2004-03-02 2005-03-02 Therapieüberwachung für tumoren unter benutzung acc133 mrna

Country Status (4)

Country Link
EP (2) EP1571225A1 (de)
AT (1) ATE432997T1 (de)
CA (1) CA2558604A1 (de)
WO (1) WO2005083123A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005289415A1 (en) * 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
WO2008003013A2 (en) * 2006-06-29 2008-01-03 Abbott Laboratories Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic
WO2008016890A1 (en) * 2006-07-31 2008-02-07 Abbott Laboratories Antitumorigenic drug combination
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
US20120100997A1 (en) * 2009-04-24 2012-04-26 University Of Southern California Cd133 polymorphisms and expression predict clinical outcome in patients with cancer
US20130011488A1 (en) * 2011-07-07 2013-01-10 Nezami Md Mohammad Systems, Methods, and Formulations for Treating Cancer
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR102138249B1 (ko) * 2018-10-30 2020-07-27 서울대학교산학협력단 유방암 진단용 바이오마커 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4472253B2 (ja) * 2000-12-04 2010-06-02 プリマゲン ベー．フェー． 内部共生体細胞小器官の検査およびそれで識別可能な化合物
JP2004528028A (ja) * 2001-03-07 2004-09-16 バイオメリオ・ベー・ベー 転写による増幅を使用したｄｎａの増幅及び検出法
AU2003206865B2 (en) * 2002-02-08 2007-10-04 D. Collen Research Foundation Vzw A novel target to inhibit angiogenesis
US7252976B2 (en) * 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample

Also Published As

Publication number Publication date
CA2558604A1 (en) 2005-09-09
EP1571225A1 (de) 2005-09-07
EP1725679B1 (de) 2009-06-03
EP1725679A1 (de) 2006-11-29
WO2005083123A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
ATE432997T1 (de) Therapieüberwachung für tumoren unter benutzung acc133 mrna
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
ATE540319T1 (de) Verfahren für die bestimmung von fk506
WO2008063413A3 (en) Gene expression profiling for identification, monitoring, and treatment of lung cancer
WO2006055524A3 (en) Biomarkers for diagnosing schizophrenia and bipolar disorder
WO2010019550A3 (en) Method of identifying disease risk factors
WO2007126758A3 (en) Method and system for determining whether a drug will be effective on a patient with a disease
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
WO2006074367A3 (en) Method of predicting and reducing risk of metastasis of breast cancer to lung
CY1111612T1 (el) Μεθοδος για προβλεψη της αποκρισης σε μια θεραπευτικη αγωγη με εναν αναστολεαδιmερισmου του her
WO2006036744A3 (en) Methods for a global assay of coagulation and fibrinolysis
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
WO2006012468A3 (en) Detection of oligonuleotides by dual hybridization
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
BRPI0607507A2 (pt) método in vitro para a identificação de compostos para tratamento do cáncer
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
WO2006138646A3 (en) Protein profile for osteoarthritis
WO2005005661A3 (en) Genes regulated in ovarian cancer as prognostic and therapeutic targets
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
WO2004113574A3 (en) Methods for disease screening
DE602006015221D1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
WO2012074550A3 (en) Methods to assess treatment outcomes in reward deficiency syndrome (rds) behaviors utilizing expression profiling
WO2009068423A3 (en) Method for predicting therapy responsiveness in basal like tumors
ATE494556T1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties